Pediatric Praziquantel Consortium

From the Program Lead: We have entered the pivotal Phase III stage!

31 October 2018

With the Phase II trial showing good results on safety and efficacy for the new orally dispersible praziquantel...

Schistosomiasis in Kenya: an interview with Dr. Maurice R. Odiere

31 October 2018

The forthcoming Phase III clinical trial of the Pediatric Praziquantel (PZQ) Consortium Formulation program will be...

A story of schistosomiasis infection in Ghana

A story of schistosomiasis infection in Ghana.
Video credit: Shelly Xie


Our vision is to reduce the global disease burden of schistosomiasis by addressing the medical need of infected preschool-age children including infants and toddlers.

Read more


Our mission is to develop, register and provide access to a suitable pediatric praziquantel formulation for treating schistosomiasis in preschool-age children.

Read more

Development program

Soon after its formation, the consortium established a pediatric drug development program, divided into two major steps: preclinical development, and clinical development.

Read more

The pediatric formulation

A new child-appropriate praziquantel formulation is essential for treating children under 6 years of age. The formulation is a small, orally dispersible tablet with an acceptable taste.

Read more